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202 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 1 – 2 0 4In the absence of conclusive data indicating cost-effective-
ess of RSV prophylaxis, should we as a society deny high-risk
nfants an effective preventative therapy in the following setting
here 1) there is no RSV vaccine; 2) there are no effective RSV
reatments; and 3) the target population is both young in age and
mall in numbers? A budget impact model may be most infor-
ative when cost-effectiveness is inconclusive.
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ssues and failed to cite relevant articles on the analysis of
ncertainty in economic models.
The author failed to cite the work of Claxton et al. [2], who
tate that the choice of distribution for uncertain inputs
hould be guided by the form of the data, the type of parame-
er and the estimation process, and a discussion that details
he issue of reflecting uncertainty in economic models.
The author suggests that parametric bootstrapping is used
o propagate parameter uncertainty through an economic
odel whereas the most common approach is to use Monte
arlo simulation [2], although other approaches are availableThe author failed to distinguish adequately between epis-
emic and aleatory uncertainty. Epistemic uncertainty arises
rom a lack of knowledge and may be reduced or even elimi-
ated by obtaining more information, whereas aleatory un-
ertainty is due to randomness and is irreducible. The meth-
ds for estimating a confidence interval for an incremental
ost-effectiveness ratio described by the author are frequen-
ist methods for patient-level analyses and are not relevant to
discussion on the analysis of economic models.
It is questionable under what circumstance the “effect
ize” from an economic model will be presented using a rela-
ive risk (RR) because, in health economics, we are interested
n outcome measures that can be valued in the sense that K
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203V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 0 1 – 2 0 4nits of benefit are worth K times as much as one unit of
enefit, and this is unlikely to apply to an RR.
The author’s notation is imprecise; for example, in Equa-
ion 7 the author writes (with minor alteration):
X  exp 122
 explnRR 12SE[ln(RR)]2.
The second line cannot be true because ln(RR) and SE[ln(RR)]2
re sample estimates of population parameters, whereas the
rst line is the population mean. Again, the author is being im-
recise about epistemic and aleatory uncertainty.
Although the author is effectively proposing a frequentist
olution to his concern about the mean of the RR, from a
ayesian perspective it is not necessary to estimate the pop-
lation RR by the mean of its posterior distribution, and the
osterior median can be used as a central estimate instead [5].
ndeed, it is questionable in what sense the author’s proposal
s actually required in the context of propagating parameter
ncertainty through an economic model because parameter
ncertainty only applies in Bayesian statistics.
Finally, the author should be aware that uncertainty anal-
sis involves propagating parameter uncertainty through an
conomic model, whereas probabilistic sensitivity analysis
ntails exploring how the inputs contribute to the output un-ertainty [6].
rticle, but my first criterion is exactly what Claxton and coau-
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2004;66:751–69.ncertainty analysis is inherently Bayesian—Reply to letter
o the editor by John Stevensthank Mr. Stevens for his interest in my article [1,2]. However,
t would seem his remarks are mostly based on misunder-
tandings.
In my article, the term “effect size” is used in the epidemi-
logical sense: the effect of a medical intervention on disease
ncidence, for example. This effect size is typically expressed
s a relative risk or odds ratio. The “effect size from an eco-
omic model” would indeed not be expressed as a relative
isk, but I have never previously seen the outcome from an
conomic model being referred to as “effect size.”
Terminology in uncertainty analysis is rather fluid. The text
n the article uses “parametric bootstrap” and “Monte Carlo sim-
lation” interchangeably. “Probabilistic sensitivity analysis” is
ometimes indeed defined as assessing the contribution of the
ncertainty in inputs to the outcome uncertainty, and in fact
hat is the definition I prefer [3]. However, in many cases it is
sed interchangeably with uncertainty analysis; an example
ould be the article by Claxton et al. [4], which Mr. Stevens wants
e to refer to in my article. Incidentally, I may not have cited thathors (Sculpher and Briggs, among others) argue for [4]. This is
ot surprising because in my article I refer to the book by
riggs, Sculpher, and Claxton [5].
I don’t think I suggested that Fieller’s theorem and the ap-
roximate methods to obtain a confidence interval for an incre-
ental cost-effectiveness ratio can be used to analyze economic
odels. In addition, I do think it is abundantly clear from my
rticle that it is about sampling uncertainty only, because that is
hat is expressed by the confidence interval of a relative risk.
The complete quote from my article, with the equations, is:
When X has a Lognormal distribution with parameters
 ln(RR) and   SE[ln(RR)] then the following holds [6]:
eanX  exp 122
 explnRR 12SElnRR2.
Given the sentence immediately preceding the equations
which was omitted by Mr. Stevens), the second line is math-
